본문 바로가기
KERD
논문KCI 등재

An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians

Austin Granatowicz|Caroline I. Piatek|Elizabeth Moschiano|Ihab El-Hemaidi|Joel D. Armitage|Mojtaba Akhtari
대한가정의학회 (The Korean Academy Of Family Medicine)|2015.09|Korean Journal of Family Medicine|제36권 제5호|pp. 197-202

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

ChronicPrimary Health CareLeukemiaMyelogenousBCR-ABL Positive
주제분류가정의학

초록

Chronic myeloid leukemia (CML) accounts for approximately 15% of adult leukemias. Forty percent of patients with CML are asymptomatic, in whom the disease is detected solely based on laboratory abnormalities. Since the introduction of tyrosine kinase inhibitor therapy in 2001, CML has become a chronic disease for the majority of patients. Primary care physicians may be the first to recognize a new diagnosis of CML. In patients with known CML, the primary care physician may be the first to detect disease progression or adverse effects to therapy. This article provides an overview of the clinical presentation, diagnostic approach, and treatment considerations of CML.

Abstract

Chronic myeloid leukemia (CML) accounts for approximately 15% of adult leukemias. Forty percent of patients with CML are asymptomatic, in whom the disease is detected solely based on laboratory abnormalities. Since the introduction of tyrosine kinase inhibitor therapy in 2001, CML has become a chronic disease for the majority of patients. Primary care physicians may be the first to recognize a new diagnosis of CML. In patients with known CML, the primary care physician may be the first to detect disease progression or adverse effects to therapy. This article provides an overview of the clinical presentation, diagnostic approach, and treatment considerations of CML.

참고문헌 (42)

  1. Siegel RL, "Cancer statistics, 2015", Cancer J Clin, 65, pp.5~29 (2015)
  2. "SEER cancer statistics factsheets: chronic myeloid leukemia" (2014)[URL]
  3. Kantarjian H, "Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience", Blood, 119, pp.1981~1987 (2012)
  4. Huang X, "Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy", Cancer, 118, pp.3123~3127 (2012)
  5. Rowley JD., "Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining", Nature, 243, pp.290~293 (1973)
  6. Sawyers CL., "Chronic myeloid leukemia", N Engl J Med, 340, pp.1330~1340 (1999)
  7. Kantarjian HM, "Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia", Am J Med, 88, pp.1~8 (1990)
  8. Baccarani M, "European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013", Blood, 122, pp.872~884 (2013)
  9. Swerdlow SH, "World Health Organization classification of tumours of haematopoietic and lymphoid tissues" (2008), International Agency for Research on Cancer Press
  10. Faderl S, "The biology of chronic myeloid leukemia", N Engl J Med, 341, pp.164~172 (1999)
  11. Savage DG, "Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period", Br J Haematol, 96, pp.111~116 (1997)
  12. O’Brien S, "Chronic myelogenous leukemia, version 1.2015", J Natl Compr Canc Netw, 12, pp.1590~1610 (2014)
  13. O’Brien SG, "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia", N Engl J Med, 348, pp.994~1004 (2003)
  14. Sokal JE, "Prognostic discrimination in “good-risk” chronic granulocytic leukemia", Blood, 63, pp.789~799 (1984)
  15. Hasford J, "A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group", J Natl Cancer Inst, 90, pp.850~858 (1998)
  16. Jabbour E, "Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)", Blood, 123, pp.494~500 (2014)
  17. Kantarjian HM, "Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)", Blood, 119, pp.1123~1129 (2012)
  18. Larson RA, "Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase:ENESTnd 3-year follow-up", Leukemia, 26, pp.2197~2203 (2012)
  19. Larson RA, "ENESTnd 5-year (y) update: long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM)", J Clin Oncol, 32(15_suppl), pp.7073~ (2014)
  20. Cortes JE, "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias", N Engl J Med, 369, pp.1783~1796 (2013)
  21. Food and Drug Administration, "FDA drug safety communication: FDA investigating leukemia drug Iclusig (ponatinib) after increased reports of serious blood clots in arteries and veins" (2013), Food and Drug Administration
  22. Hochhaus A, "Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia", Leukemia, 23, pp.1054~1061 (2009)
  23. "Ponatinib" (2012)[URL]
  24. Akhtari M, "Imatinib: chemical structure, pharmacology and adverse effects", pp.65~80 (2013), Nova Science Publishers Inc
  25. Mahon FX, "Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years:the prospective, multicentre Stop Imatinib (STIM) trial", Lancet Oncol, 11, pp.1029~1035 (2010)
  26. Ross DM, "Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR", Leukemia, 24, pp.1719~1724 (2010)
  27. Cortes JE, "Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib", Clin Lymphoma Myeloma Leuk, 13, pp.584~591 (2013)
  28. Cortes J, "Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation", Blood, 120, pp.2573~2580 (2012)
  29. Pye SM, "The effects of imatinib on pregnancy outcome", Blood, 111, pp.5505~5508 (2008)
  30. Cortes J, "How I treat newly diagnosed chronic phase CML", Blood, 120, pp.1390~1397 (2012)
  31. El-Hemaidi I, "Management of haematological malignancy in pregnancy", Best Pract Res Clin Obstet Gynaecol, 26, pp.149~160 (2012)
  32. Baer MR, "Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia", Br J Haematol, 81, pp.167~169 (1992)
  33. Kuroiwa M, "Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy", Am J Hematol, 59, pp.101~102 (1998)
  34. Delmer A, "Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia", Br J Haematol, 82, pp.783~784 (1992)
  35. Patel M, "Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report", Am J Obstet Gynecol, 165, pp.565~566 (1991)
  36. Tertian G, "Hydroxyurea and pregnancy", Am J Obstet Gynecol, 166(6 Pt 1), pp.1868~ (1992)
  37. Jackson N, "Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy", Br J Haematol, 85, pp.203~204 (1993)
  38. Baykal C, "Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy:a case report", Eur J Gynaecol Oncol, 21, pp.89~90 (2000)
  39. Celiloglu M, "Hydroxyurea treatment for chronic myeloid leukemia during pregnancy", Acta Obstet Gynecol Scand, 79, pp.803~804 (2000)
  40. Ault P, "Pregnancy among patients with chronic myeloid leukemia treated with imatinib", J Clin Oncol, 24, pp.1204~1208 (2006)
  41. Ramasamy K, "Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy", Br J Haematol, 137, pp.374~375 (2007)
  42. Cortes J, "Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib", Blood, 112, pp.Abstract 3~ (2008)

관련 논문AI추천

Rapid Sequential Gain of ABL1 Kinase Domain Mutations with a Complex Karyotype in the Progression of Chronic Myelogenous Leukemia공선영, 박선섭, 심효은, 엄혜석, 이혜원, 정유선, 조은해대한진단검사의학회 · Annals of Laboratory Medicine2014 · 제34권 제5호Hidden “Preleukemic Phase” of Chronic Myeloid Leukemia Presenting Without Leukocytosis in the Peripheral Blood Unrelated to Chemotherapy in a Patient Diagnosed With Diffuse Large B Cell Lymphoma김인숙, 김형회, 박상혁, 유동원, 이은엽, 이종윤, 장철훈대한진단검사의학회 · Annals of Laboratory Medicine2017 · 제37권 제5호Four Cases of Chronic Myelogenous Leukemia in Mixed Phenotype Blast Phase at Initial Presentation Mimicking Mixed Phenotype Acute Leukemia with t(9;22)이석, 김명신, 김용구, 이재욱, 임지향, 정낙균, 최우진, 한경자대한진단검사의학회 · Annals of Laboratory Medicine2014 · 제34권 제1호만성골수성백혈병 치료제의 효과: 메타분석유기연한국병원약사회 · 병원약사회지2013 · 제30권 제4호A Primary Care Approach to Myelodysplastic SyndromesDjamshed Samiev, Joel D. Armitage, Lori J Maness, Mojtaba Akhtari, Vijaya R. Bhatt대한가정의학회 · Korean Journal of Family Medicine2014 · 제35권 제3호Promyelocytic Blast Phase of Chronic Myeloid Leukemia, BCR-ABL1 -Positive: Points to be Considered at DiagnosisChi Hyun Young, Choi Young-Jin, Kim Bohyun, Yoon Young Ahn대한진단검사의학회 · Annals of Laboratory Medicine2021 · 제41권 제3호

이 간행물의 다른 논문 (11건)

Barrier Factors to the Completion of Diabetes Education in Korean Diabetic Adult Patients: Korea National Health and Nutrition Examination Surveys 2007-2012Yoon-Jung Choi, 정수민, 이기헌, 정세영, Seung-Min Oh, Hee-Tae Kimpp. 203-209Perceived Stress, Alexithymia, and Psychological Health as Predictors of Sedative AbuseSaeid Komasi, Seyed Ramin Ghasemi, Sohyla Reshadat, Ali Zakiei, Nader Rajabi Gilanpp. 210-215Breast Feeding Is Associated with Postmenopausal Bone Loss: Findings from the Korea National Health and Nutrition Examination SurveyHyun Joo Kim, Youngju Kim, Sang Hyun Ahn, Seung-Won Oh, Hyuktae Kwon, Cheol Min Lee, Hee-Kyung Joh, Yoo-Jin Umpp. 216-220Time to First Cigarette and Hypertension in Korean Male Smokers이새롬, 송홍지, 장미애, 오혜영, 노혜미, 백유진, 박경희pp. 221-226Association between Helicobacter pylori Infection and Cerebral Small Vessel DiseaseDong Wook Shin, Jae Moon Yun, 정수민, Hyun Ho Kim, Soo Hyun Jang, Hyejin Lee, 박진호, 조비룡, Sang-Hyun Lee, Hyun Jung Park, Jun Suk Kim, 권형민pp. 227-232
원문 보기